Southborough, MA--ACMI Corp. has launched the all-digital Invisio Flexible CystoNephroscope (ICN). Compared with traditional fiber optic endoscopes, the product has seven times better resolution and a lower total cost of ownership.
Digital endoscope offers improved resolutionSouthborough, MA-ACMI Corp. has launched the all-digital Invisio Flexible CystoNephroscope (ICN). Compared with traditional fiber optic endoscopes, the product has seven times better resolution and a lower total cost of ownership.
For more information, visit http://www.acmicorp.com/.
An additional capability is the Dornier UIMS (urology information management system), a digital imaging system that combines a high-end patient data management system with comprehensive DICOM capabilities. This system is simple to use and can be integrated into the hospital or clinic network.
For more information, call (770) 426-1315; http://www.dornier.com/.
Urethral stent allows urine to flow freelyNeedham, MA-Fossa Medical's Open-I urethral stent lasts longer, resists more compression, and is more comfortable than a standard tubular stent, according to the company. The lumen's open configuration allows urine to flow freely inside and around the stent, thereby reducing compaction of encrustation.
Its I-Beam design creates greater structural integrity to resist closure due to external pressure, the company says. The product's flexibility is due to movable flanges and a slimmer bladder.
For more information, visit http://www.fossamedical.com/.
LED headset system provides dual pivot pointsCherry Hill, NJ- The Bright Star LED headset system from Vision USA offers various viewing options. The adjustable knob and cushioned head loupe provide comfort and convenience, the company says.
The system features a bright, direct LED light with dual pivot points. The headset is available alone or with +1.5-, +2.0-, and +2.5-range clip-on magnifiers, which are sold separately. AAA batteries are included.
For more information, call (800) 257-5782; http://www.visionusa.biz/.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.